Clinical Trials
- Immune System
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
- Ages18 years - 75 years
- GenderBoth
- Date04/27/2021
- Orthopaedics, Muscle & Bone
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)
- Ages16 years and older
- GenderBoth
- Date03/25/2022
- Skin/Dermatology
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata (AZURE)
- Ages18 years - 75 years
- GenderBoth
- Date05/10/2022
- Orthopaedics, Muscle & Bone
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
- Ages18 years - 70 years
- GenderBoth
- Date05/06/2021
- Stomach and Esophagus, Head and Neck Cancers, Thyroid and Other Endocrine Cancers, Phase 1 Cancers
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Ages18 years and older
- GenderBoth
- Date12/17/2019
- Immune System
Yale Lupus and Connective Tissue Disease Bio-Repository / Yale Rheumatology Bio-Repository
- Ages18 years and older
- GenderBoth
- Date10/01/2016
- Skin/Dermatology, Immune System
Genome Research in African American Scleroderma Patients (GRASP Study)
- Ages18 years and older
- GenderBoth
- Date03/17/2020
- Skin/Dermatology, Genetics
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (VAPAUS)
- Ages18 years and older
- GenderBoth
- Date01/14/2022
- Orthopaedics, Muscle & Bone, Immune System
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (NAIVE)
- Ages18 years - 70 years
- GenderBoth
- Date10/08/2021
- Skin/Dermatology, Orthopaedics, Muscle & Bone
The Scleroderma Patient-centered Intervention Network (SPIN)
- Ages18 years and older
- GenderBoth
- Date02/23/2020